Reactive Oxygen Species-Mediated Apoptosis and Cytotoxicity of Newly Synthesized Pyridazin-3-Ones In P815 (Murin Mastocytoma) Cell Line

Abstract

Background In cancer cells, the intracellular antioxidant capacity and the redox homeostasis are mainly maintained by the glutathione- and thioredoxin-dependent systems which are considered as promising targets for anticancer drugs. Pyridazinones constitute an interesting source of heterocyclic compounds for drug discovery. The present investigation focused on studying the in-vitro antitumor activity of newly synthesized Pyridazin-3(2h)-ones derivatives against P815 (Murin mastocytoma) cell line.

Methods The in-vitro cytotoxic activities were investigated toward the P815 cell line using tetrazolium-based MTT assay. Lipid peroxidation and the specific activities of antioxidant enzymes were also determined.

Results The newly compounds had a selective dose-dependent cytotoxic effect without affecting normal cells (PBMCs). Apoptosis was further confirmed through the characteristic apoptotic morphological changes and DNA fragmentation. Two compounds (6f and 7h) were highly cytotoxic and were submitted to extend biological testing to determine the likely mechanisms of their cytotoxicity. Results showed that these molecules may induce cytotoxicity via disturbing the redox homeostasis. Importantly, the anticancer activity of 6f and 7h could be due to the intracellular reactive oxygen species hypergeneration through significant loss of glutathione reductase and thioredoxin reductase activities. This eventually leads to oxidative stress-mediated P815 cell apoptosis. Furthermore, the co-administration of 6f or 7h with Methotrexate exhibited a synergistic cytotoxic effect.

Conclusions considering their significant anticancer activity and chemosensitivity, 6f and 7h may improve the therapeutic efficacy of the current treatment for cancer.

Key words

anticancer agent - oxidative stress - thioredoxin system - glutathione system - antioxidant enzymes

• References

• 1 Davis MB, Newman LA. Breast cancer disparities: How can we leverage genomics to improve outcomes?. Surg Oncol Clin N Am 2018; 27: 217-234
• 2 Clémence D, Robin D, Pierre D. et al. Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines. Oncotarget 2017; 8: 95316
• 3 Karihtala P, Kauppila S, Soini Y. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC cancer 2011; 11: 262
• 4 Kato S, Kurasaki K, Ikeda S. et al. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. Oncologist 2018; 23: 171-178
• 5 Pongkittiphan V, Chavasiri W, Supabphol R. Antioxidant effect of berberine and its phenolic derivatives against human fibrosarcoma cells. Asian Pac J Cancer Prev 2015; 16: 5371-5376
• 6 Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?. Nat Rev Drug Discov 2009; 8: 579
• 7 Luo Z, Yu L, Yang F. et al. Ruthenium polypyridyl complexes as indu gcer of ROS-mediated apoptosis in cancer cells by targeting thioredoxin reductase. Metallomics 2014; 6: 1480-1490
• 8 Hwang GH, Ryu JM, Jeon YJ. et al. The role of thioredoxin reductase and glutathione reductase in plumbagin-induced, reactive oxygen species-mediated apoptosis in cancer cell lines. Eur J Pharmacol 2015; 765: 384-393
• 9 Ren A, Liu R, Miao ZG. et al. Hydrogen-rich water regulates effects of ROS balance on morphology, growth and secondary metabolism via glutathione peroxidase in Ganoderma lucidum. Environ Microbiol 2017; 19: 566-583
• 10 Gelman SJ, Naser F, Mahieu NG. et al. Consumption of NADPH for 2-HG synthesis increases pentose phosphate pathway flux and sensitizes cells to oxidative stress. Cell Rep 2018; 22: 512-522
• 11 Halldorsson S, Rohatgi N, Magnusdottir M. et al. Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition. Cancer Lett 2017; 396: 117-129
• 12 Pollak N, Dölle C, Ziegler M. The power to reduce: Pyridine nucleotides–small molecules with a multitude of functions. Biochem J 2007; 402: 205-218
• 13 Moreno-Sánchez R, Marín-Hernández Á, Del Mazo-Monsalvo I. et al. Assessment of the low inhibitory specificity of oxamate, aminooxyacetate and dichloroacetate on cancer energy metabolism. BBA-Gen Subjects 2017; 1861: 3221-3236
• 14 Ward PS, Patel J, Wise DR. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer cell 2010; 17: 225-234
• 15 Murty MSR, Ram KR, Rao RV. et al. Synthesis and preliminary evaluation of 2-substituted-1, 3-benzoxazole and 3-[(3-substituted) propyl]-1, 3-benzoxazol-2 (3H)-one derivatives as potent anticancer agents. Med Chem Res 2011; 20: 576-586
• 16 Boxer MB, Jiang JK, Vander Heiden MG. et al. Evaluation of substituted N, N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem 2009; 53: 1048-1055
• 17 Pogacic V, Bullock AN, Fedorov O. et al. Structural analysis identifies imidazo [1, 2-b] pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007; 67: 6916-6924
• 18 Natarajan K, Bhullar J, Shukla S. et al. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and-independent mechanisms. Biochem Pharmacol 2013; 85: 514-524
• 19 Chen LS, Redkar S, Taverna P. et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011; 118: 693-702
• 20 Foulks JM, Carpenter KJ, Luo B. et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia 2014; 16: 403-412
• 21 Brault L, Menter T, Obermann EC. et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer 2012; 107: 491
• 22 Asif M. The anticancer potential of various substituted pyridazines and related compounds. Int J Adv Chem 2014; 2: 148-161
• 23 Rathish IG, Javed K, Ahmad S. et al. Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones. Eur J Med Chem 2012; 49: 304-309
• 24 Bansal R, Thota S. Pyridazin-3(2H)-ones: the versatile pharmacophore of medicinal significance. Med Chem Res 2013; 22: 2539-2552
• 25 Bouchmaa N, Tilaoui M, Boukharsa Y. et al. In Vitro Antitumor Activity of Newly Synthesized Pyridazin-3 (2h)-One Derivatives via Apoptosis Induction. Pharm Chem J 2018; 1-9
• 26 Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446
• 27 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358
• 28 Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976; 71: 952-958
• 29 Carlberg INCER and Mannervik BENGT. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem 1975; 250: 5475-5480
• 30 Lim HW, Hong S, Jin W. et al. Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells. Exp Mol Med 2005; 37: 497
• 31 Leterrier M, del Río LA, Corpas FJ. Cytosolic NADP-isocitrate dehydrogenase of pea plants: Genomic clone characterization and functional analysis under abiotic stress conditions. Free Radic Res 2007; 41: 191-199
• 32 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 33 Thoer A, Denis G, Delmas M. et al. The Reimer-Tiemann reaction in slightly hydrated solid-liquid medium: A new method for the synthesis of formyl and diformyl phenols. Synthetic Commun 1988; 18: 2095-2101
• 34 Hirota T, Fujita H, Sasaki K. et al. A novel synthesis of benzofuran and related compounds. III. The vilsmeier reaction of phenoxyacetaldehyde diethyl acetals. J Heterocyclic Chem 1986; 23: 1715-1716
• 35 Benmoussa B, D'Haen J, Borschel C. et al. Hexagonal boron nitride nanowalls: Physical vapour deposition, 2D/3D morphology and spectroscopic analysis. J Phys D Appl Phys 2012; 45: 135302
• 36 Liberski PP. Cell death and autophagy in prion diseases. In: Prion Diseases.. New York: Humana Press; 2017: 145-158
• 37 Ibrahim MA, Elmenoufy AH, Elagawany M. et al. Pyridopyridazine: A versatile nucleus in pharmaceutical field. J Biosci Med 2015; 3: 59
• 38 Pau A, Murineddu G, Asproni B. et al. Synthesis and cytotoxicity of novel hexahydrothienocycloheptapyridazinone derivatives. Molecules 2009; 14: 3494-3508
• 39 Malinka W, Redzicka A, Lozach O. New derivatives of pyrrolo [3, 4-d] pyridazinone and their anticancer effects. Farmaco 2004; 59: 457-462
• 40 Rodriguez VM, Del Razo LM, Limon-Pacheco JH. et al. Glutathione reductase inhibition and methylated arsenic distribution in Cd1 mice brain and liver. Toxicol Sci 2004; 84: 157-166
• 41 Prast-Nielsen S, Huang HH, Williams DL. Thioredoxin glutathione reductase: Its role in redox biology and potential as a target for drugs against neglected diseases. BBA-Gen Subjects 2011; 1810: 1262-1271
• 42 Cai W, Zhang L, Song Y. et al. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 2012; 52: 257-265
• 43 Go YM, Jones DP. Thiol/disulfide redox states in signaling and sensing. Crit Rev Biochem Mol Biol 2013; 48: 173-181
• 44 Zhao Y, Seefeldt T, Chen W. et al. Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiation. Free Radic Biol Med 2009; 47: 176-183
• 45 Khan MA, Chen HC, Wan XX. et al. Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 2013; 35: 219